The incidence of stent thrombosis (ST) may have declined over the last several years. We studied the temporal change in the incidence of ST in the context of continuously improving antiplatelet regimen (AR) and coronary stent (CS) technology.
Results:
The study sample included 4460 pts. Of those, 210 pts (4.7%) developed ST (71: definite, 22: probable, 117: possible) . Pts with ST (compared to without ST) were older (68±13 vs 62±13, p<0.0001); had higher smoking (53% vs 32%, p<0.0001), diabetes (67% vs 28%, p=0.009), STEMI (43% vs 33%, p=0.005), average stent/patient (1.8±1.0 vs 1.6±0.9, p<0.0001); less drug eluting CS/patient (57% vs 68%, p=0.0005) and lower use of prasugrel or ticagrelor (as part of AR) after index PCI (13% vs 22%, p=0.006). Both groups were comparable with respect to gender and lesion characteristics. Incidence of stent thrombosis, AR and CS type for pts with ST is described in Table 1 . 
